Clinical trials
Hepatic Impairment clinical trials
Below are recruiting hepatic impairment clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07809802RecruitingPhase 1
Study of vorolanib tablets in people with liver problems
This study looks at how the body handles the study drug vorolanib (taken as a tablet) when your liver is impaired. It might help doctors understand the right dose for people with liver problems, and it may also benefit those who are newly diagnosed or exploring treatment options.
Changchun, JilinAges 18–70 - NCT07694843RecruitingPhase 1
Study of ammoxetine for people with mild to moderate liver problems
This trial tests how the body processes ammoxetine in people with mild or moderate liver impairment compared to people with normal liver function. It aims to find out if the drug is safe and how it works in these groups.
Suzhou, JiangsuAges 18–75 - NCT07643155RecruitingPhase 1
Safety study of inhaled treprostinil in people with liver disease
This early-stage study tests how the body processes a new inhaled breathing medication (treprostinil) and whether it's safe in people with normal liver function and those with chronic liver disease. The goal is to understand if the medication works differently depending on liver health.
Lake Forest, CaliforniaAges 18–70 - NCT07457229RecruitingPhase 1
Study of Radiprodil in People With Liver Problems
This study tests a drug called radiprodil in people with different levels of liver problems. It helps doctors understand how the liver processes the drug, which could make future treatments safer.
DeSoto, TexasAges 18–75 - NCT06985615RecruitingPhase 1
Study of HDM1002 in people with and without liver problems
This trial tests a medicine called HDM1002 in people who have different levels of liver function. It aims to see how the liver affects the drug and if it is safe.
Suzhou, JiangsuAges 18–70 - NCT06962332RecruitingPhase 1
Study of Zanzalintinib in People with Moderate Liver Problems
This trial looks at how a drug called Zanzalintinib acts in people with moderate liver impairment compared to healthy volunteers. It aims to ensure the drug is safe and at the right dose for people with liver issues.
Orlando, FloridaAges 18–75 - NCT06740799RecruitingPhase 1
Quizartinib study for people with severe liver problems
This trial tests how the body processes quizartinib when the liver is severely impaired. It helps doctors understand if the dose needs to be adjusted for patients with liver issues.
Miami, FloridaAges 18–75 - NCT07715149RecruitingPhase 1
D-2570 study for people with and without liver issues
This trial tests how a drug called D-2570 is processed in people with different levels of liver function. It compares people with liver impairment to those with healthy livers to see how the drug moves through the body.
Bengbu, AnhuiAges 18–70 - NCT07682818RecruitingPhase 1
Petrelintide in people with liver impairment
This trial tests how a drug called petrelintide is processed in people with different levels of liver function. It may help doctors understand how to dose the drug safely for patients with liver disease, including those with type 2 diabetes.
Wroclaw, PolandAges 18–70 - NCT07343960RecruitingPhase 1
Study of Capivasertib in people with moderate liver impairment
This trial tests how the drug capivasertib is processed by the body and how safe it is in people with moderate liver impairment. It aims to find the right dose for patients whose liver function is reduced but stable.
Rialto, CaliforniaAges 18–80 - NCT07250633RecruitingPhase 1
Study of Vorasidenib in severe liver disease and healthy volunteers
This trial tests how the drug vorasidenib behaves in people with severe liver problems compared to healthy volunteers. It helps doctors understand if the drug needs different dosing for patients with liver disease.
Chandler, ArizonaAges 18–75 - NCT07422610RecruitingPhase 1
Study of Pelabresib for advanced cancer with liver issues
This trial tests how the drug pelabresib works in people with advanced cancer who also have mild to severe liver problems. It aims to understand safety and how the drug moves through the body.
BordeauxAges 18–75 - NCT07844967RecruitingPhase 1
How the liver affects a new medicine
This study tests a new medicine for people with mild or moderate liver problems to see how the liver affects the drug in the body. It also includes people with normal liver function for comparison.
Hefei, AnhuiAges 18 years+ - NCT07751250RecruitingPhase 1
Casdatifan in moderate liver impairment
This study looks at how a new drug, casdatifan, is processed in the body in people with moderate liver problems compared to healthy people. Understanding this helps doctors decide if the drug is safe and how to dose it for patients with liver issues.
San Antonio, TexasAges 18–84 - NCT07546760RecruitingPhase 1
Study of how liver disease affects two new medications
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
Chandler, ArizonaAges 18–85 - NCT04271488RecruitingPhase 1
Study drug levels in people with mild or moderate liver problems
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
Hakata, FukuokaAges 20–79 - NCT07231029RecruitingPhase 1
Study of TS-172 in people with reduced liver function
This study tests how an experimental drug (TS-172) is processed in the body by comparing people with mild to moderate liver disease to those with normal liver function. It may help doctors understand how to dose the drug safely for people with liver problems.
TokyoAges 18–75 - NCT07144111RecruitingPhase 1
Liver Function and Inavolisib Study
This study tests how the body processes the drug inavolisib when taken by people with moderate or severe liver problems compared to those with healthy livers. It helps doctors understand the right dose for patients with liver impairment.
Lake Forest, CaliforniaAges 18–80 - NCT06997276RecruitingPhase 1
How the liver affects the drug mirdametinib
This study looks at how mirdametinib is processed in people with liver problems compared to healthy people. It will help doctors understand if the dose needs to be adjusted.
Miami, FloridaAges 18–80 - NCT05045482RecruitingPhase 1
Study drug in people with cirrhosis from blocked bile flow
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
Indianapolis, IndianaAges 18–80 - NCT07559474RecruitingPhase 1
Safety Study of INCB123667 in Adults With Liver Damage
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
Chandler, ArizonaAges 18–80 - NCT07677358RecruitingPhase 1
Atirmociclib in people with normal or reduced liver function
This study tests how the body handles the medicine Atirmociclib in people with different levels of liver function, from normal to moderate or severe liver disease. It helps doctors understand if the dose needs to be adjusted for people with liver problems.
Miami Lakes, FloridaAges 18 years+ - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07654855Recruiting
Long-term safety of eplontersen in ATTR patients
This study follows people who already took part in an earlier trial (D8450R00003) to see how safe eplontersen is over the long term. It also includes people who had a liver transplant or severe liver problems.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Hepatic Impairment trials by city
Studies with a site in or near these metro areas.
Hepatic Impairment trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hepatic impairment?
- Yes. Clin2 currently lists 35 recruiting hepatic impairment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatic impairment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatic impairment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.